Buprenorphine

This manual provides guidelines for operating an opioid treatment program. It covers patient-centered care planning, assessment, admission, and monitoring; medication administration and use; medical and clinical provisions and practices; certification and accreditation; and the importance of practitioner judgment in providing care.

Provides a basic introduction of the concepts of the disease of addiction and the role of the reward system. Using neuroscience concepts as a foundation, clinical manifestations of the disease of addiction are then discussed in the form of case-based presentations. 

Outlines the basic concepts of alcohol and drug use disorders. Standard drink sizes, screening for alcohol use disorders and an introduction to alcohol withdrawal management are discussed. A basic overview of the major drug use disorders are then discussed in a clinically-relevant manner. 

Provides an overview of the history of opioid use with an overview of contributing factors to the current epidemic. Using clinical cases, opioid use disorder is then discussed in detail. Finally, there is a discussion of harm reduction approaches and treatment options.

Introduces evidence-based clinical practices of pharmacotherapy and behavioral treatments for substance use disorders. Off label medications and psychosocial support programs are also discussed.

This podcast will be published on the SAEM website and in promotional materials, such as our weekly newsletter, to inform learners of the activity’s contents and goals.

This webinar provides essential insights into addressing the opioid overdose crisis and improving substance use care. It equips healthcare providers with evidence-based strategies for overdose prevention, including naloxone distribution, and explores innovative approaches to engage at-risk populations. Key topics include the role of substance use care providers and new methods to reduce overdose deaths.

As the opioid use crisis continues to progress, communities across the country are now being faced with additional dangers such as the misuse of Xylazine, a powerful sedative commonly used for animals in the drug supply. Recent studies indicate these potent substances when used with opioids increase overdose risk and complicates treatment and long-term healthcare. Join us today as we discuss the history and context of Xylazine and opioid use as well as options for treatment and care.

Shared decision-making (SDM) involves a collaborative discussion between the patient and clinician about treatment options, advantages and disadvantages, and helps to identify the optimal treatment based on patient-specific needs and goals.and helps to identify the optimal treatment based on patient-specific needs and goals.

This presentation will review the origins and trajectory of the current opioid epidemic, now described as being in its fourth wave. Considered will be the current epidemiology of the epidemic, particularly opioid-overdose related fatalities; the effectiveness of and potential gaps in current harm reduction strategies such as overdose education and naloxone distribution and drug checking services that provide fentanyl and xylazine test strips or on-site testing; principal barriers to expansion of buprenorphine prescribing among health care providers; and medication for opioid use disorder treatment initiation and engagement; and the science underscoring the significance of co-occurring tobacco use disorder among persons addicted to opioids and entering MOUD treatment.